[Boris Simkovich]

ASCO 2018 & multiple myeloma

by Boris Simkovich on Thu May 24, 2018 9:21 pm

The annual American Society of Clinical Oncology meeting is coming up at the end of next week. We just published a short article about the meeting.

The article includes links to lists of myeloma-related oral presentations, poster presentations, e-posters / e-abstracts, and educations session presentations associated with the meeting. Here, once again, are the links to those pages:

Are there are any oral presentations or posters related to research into

• The biology of the disease, or
• The impact of existing or potential new therapies on the disease,

that you find particularly interesting, or that you're particularly looking forward to?

[Eileenk]

Re: ASCO 2018 & multiple myeloma

by Eileenk on Wed May 30, 2018 9:04 am

Thanks for posting these links, Boris.

I find the education sessions related to the bones interesting. I will keep checking back after the conference for more details.

Eileen

[lwem]

Re: ASCO 2018 & multiple myeloma

by lwem on Wed May 30, 2018 8:32 pm

Many of these seem interesting. Of course, the updated CAR T-cell bb2121 results are something that I would want to look at.

[Boris Simkovich]

Re: ASCO 2018 & multiple myeloma

by Boris Simkovich on Sat Jun 02, 2018 2:22 pm

Just a heads up to everyone that we've uploaded to our server, and made available to our readers, full slide decks from several of the oral presentations at ASCO yesterday. Look for the links in the page listing the oral presentations:

https://myelomabeacon.org/asco-2018-multiple-myeloma-oral-presentations/

One of the slide decks is from Dr. Costa, one of the Beacon's Medical Advisors, who presented a study related to Venclexta (venetoclax). The other two are discussion presentations from Dr. Hofmeister (abstracts 8003-8005) and Dr. Hari (abstracts 8006-8008).

We getting the slides up on our server as quickly as we can get them. Sorry we can't make the process go any faster.

[Nancy Shamanna]

Re: ASCO 2018 & multiple myeloma

by Nancy Shamanna on Wed Jun 06, 2018 2:10 pm

That is an interesting study about the use of Venclexta and Kyprolis, and thanks for posting the presentation slides for the study.

It seems that the proteasome inhibitor Kyprolis plus the Venclexta, which attacks another en­zyme protecting the cancer cells, is a strong combination. I think it is interesting that Venclexta is already used for chronic leukocytic leukaemia (CLL), especially for patients with a 17p deletion, and that it appears to have efficacy in multiple myeloma patients with the t(11,14) trans­location. Venclexta is already approved by Health Canada and recommended by pCODR for the use in CLL, so if these studies prove that it was also effective against myeloma, there could be a new drug available. (I do not know if Venclexta is funded yet by any provinces, though.)

[Foundry738]

Re: ASCO 2018 & multiple myeloma

by Foundry738 on Thu Jun 07, 2018 11:17 am

Regarding Venclexta, it's an oral drug that is in some trials for Waldenstrom's macroglobulinemia and it seems to be effective and well-tolerated. It's not clear if it will need to be taken forever, or until it doesn't work, which is the case for Imbruvica (ibrutinib).